Immunocore Holdings plc ADR (IMCR) Unusual Options Activity Today

Checking IMCR unusual options activity helps you spot when traders are making outsized bets on Immunocore Holdings plc ADR before the broader market catches on. Immunocore Holdings plc ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor IMCR unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching IMCR unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking IMCR unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and IMCR unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.

In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Catalysts rarely arrive without a footprint, and IMCR unusual options activity is often where that footprint shows up first. Our scanner tracks Immunocore Holdings plc ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at IMCR unusual options volume on the call side or chasing put sweeps, Immunocore Holdings plc ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.